251 related articles for article (PubMed ID: 30067949)
1. Can tumor-associated macrophages in ductal carcinoma in situ on biopsy predict invasive carcinoma on excision?
Hoskoppal D; Reisenbichler ES
Hum Pathol; 2018 Dec; 82():158-162. PubMed ID: 30067949
[TBL] [Abstract][Full Text] [Related]
2. High EZH2 expression in ductal carcinoma in situ diagnosed on breast core needle biopsy is an independent predictive factor for upgrade on surgical excision.
Genco IS; Ozgultekin B; Hosseini H; Hackman K; Ferreira L; Santagada E; Wahl S; Hajiyeva S
Pathol Res Pract; 2020 Dec; 216(12):153283. PubMed ID: 33197837
[TBL] [Abstract][Full Text] [Related]
3. Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence.
Chen XY; Thike AA; Md Nasir ND; Koh VCY; Bay BH; Tan PH
Virchows Arch; 2020 Jun; 476(6):825-833. PubMed ID: 31897820
[TBL] [Abstract][Full Text] [Related]
4. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
5. Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.
Mori K; Takeda M; Kodama Y; Kiyokawa H; Yasojima H; Mizutani M; Otani Y; Morikawa N; Masuda N; Mano M
Hum Pathol; 2017 Jun; 64():145-155. PubMed ID: 28434924
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery.
Podoll MB; Reisenbichler ES; Roland L; Bruner A; Mizuguchi S; Sanders MAG
Arch Pathol Lab Med; 2018 Sep; 142(9):1120-1126. PubMed ID: 29582675
[TBL] [Abstract][Full Text] [Related]
7. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
8. Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score!
Marques LC; Marta GN; de Andrade JZ; Andrade D; de Barros ACSD; Andrade FEM
Eur J Surg Oncol; 2019 Jul; 45(7):1152-1155. PubMed ID: 30665684
[TBL] [Abstract][Full Text] [Related]
9. Spindle cell ductal carcinoma in situ. An unusual variant of ductal intra-epithelial neoplasia that simulates ductal hyperplasia or a myoepithelial proliferation.
Farshid G; Moinfar F; Meredith DJ; Peiterse S; Tavassoli FA
Virchows Arch; 2001 Jul; 439(1):70-7. PubMed ID: 11499843
[TBL] [Abstract][Full Text] [Related]
10. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
[TBL] [Abstract][Full Text] [Related]
11. Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.
Takada K; Kashiwagi S; Asano Y; Goto W; Morisaki T; Takahashi K; Fujita H; Takashima T; Tomita S; Hirakawa K; Ohira M
BMC Cancer; 2020 Jun; 20(1):513. PubMed ID: 32493410
[TBL] [Abstract][Full Text] [Related]
12. Preoperative clinicopathologic factors and breast magnetic resonance imaging features can predict ductal carcinoma in situ with invasive components.
Lee CW; Wu HK; Lai HW; Wu WP; Chen ST; Chen DR; Chen CJ; Kuo SJ
Eur J Radiol; 2016 Apr; 85(4):780-9. PubMed ID: 26971424
[TBL] [Abstract][Full Text] [Related]
13. [Predictive factors of invasion with initial diagnosis of ductal carcinoma in situ based on core biopsy].
Kósa C; Garami Z; Dinya T; Fülöp B
Magy Seb; 2012 Aug; 65(4):218-21. PubMed ID: 22940391
[TBL] [Abstract][Full Text] [Related]
14. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M; Stempel M; Rosenfeld H; Eaton A; Van Zee KJ; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3487-3493. PubMed ID: 27172775
[TBL] [Abstract][Full Text] [Related]
15. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.
Renshaw AA; Gould EW
Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205
[TBL] [Abstract][Full Text] [Related]
16. Reporting the greatest linear extent of ductal carcinoma in situ on needle core biopsy.
Reisenbichler ES; Hameed O
Hum Pathol; 2016 Apr; 50():140-5. PubMed ID: 26997448
[TBL] [Abstract][Full Text] [Related]
17. Pathologic assessment of tumor-associated macrophages and their histologic localization in invasive breast carcinoma.
Mwafy SE; El-Guindy DM
J Egypt Natl Canc Inst; 2020 Jan; 32(1):6. PubMed ID: 32372332
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated macrophages are strongly related to vascular invasion, non-luminal subtypes, and interval breast cancer.
Klingen TA; Chen Y; Aas H; Wik E; Akslen LA
Hum Pathol; 2017 Nov; 69():72-80. PubMed ID: 28923419
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision.
Kim J; Han W; Lee JW; You JM; Shin HC; Ahn SK; Moon HG; Cho N; Moon WK; Park IA; Noh DY
Breast; 2012 Oct; 21(5):641-5. PubMed ID: 22749854
[TBL] [Abstract][Full Text] [Related]
20. Morphologic, molecular and microenvironment factors associated with stromal invasion in breast ductal carcinoma in situ: Role of myoepithelial cells.
Aguiar FN; Cirqueira CS; Bacchi CE; Carvalho FM
Breast Dis; 2015; 35(4):249-52. PubMed ID: 26397772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
